Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OLMA
stocks logo

OLMA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.527
+3.26%
--
--
-0.550
+52.78%
--
--
-0.586
+14.9%
Estimates Revision
The market is revising Downward the revenue expectations for Olema Pharmaceuticals, Inc. (OLMA) for FY2026, with the revenue forecasts being adjusted by -12.5% over the past three months. During the same period, the stock price has changed by 232.61%.
Revenue Estimates for FY2026
Revise Downward
down Image
-12.5%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.63%
In Past 3 Month
Stock Price
Go Up
up Image
+232.61%
In Past 3 Month
Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 34.40 USD with a low forecast of 20.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 34.40 USD with a low forecast of 20.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.640
sliders
Low
20.00
Averages
34.40
High
45.00
Current: 27.640
sliders
Low
20.00
Averages
34.40
High
45.00
Goldman Sachs
Goldman Sachs
Buy
maintain
$18 -> $26
2025-11-21
Reason
Goldman Sachs
Goldman Sachs
Price Target
$18 -> $26
2025-11-21
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Olema Oncology (OLMA) to $26 from $18 and keeps a Buy rating on the shares. Roche's (RHHBY) positive Phase 3 lidERA results strengthen confidence in next-generation SERDs and improve Olema's outlook, reinforced by a recent $190M capital raise that enhances financial flexibility and trial optionality, the analyst tells investors in a research note. While the probability of success for palazestrant in 1L mBC has been increased and risk assumptions modestly reduced, meaningful uncertainties remain, particularly prior mixed giredestrant results and the complexity of non-ER mutations, leaving a cautiously optimistic stance ahead of the Phase 3 persevERA readout in 1Q26, Goldman says.
Guggenheim
Buy
upgrade
$20 -> $40
2025-11-20
Reason
Guggenheim
Price Target
$20 -> $40
2025-11-20
upgrade
Buy
Reason
Guggenheim raised the firm's price target on Olema Oncology (OLMA) to $40 from $20 and keeps a Buy rating on the shares following news earlier this week that Roche's (RHHBY) lidERA trial met its primary endpoint at a pre-planned interim analysis, showing a statistically significant and clinically meaningful improvement in invasive disease-free survival with giredestrant versus standard-of-care endocrine therapy. Following Roche's Phase 3 lidERA adjuvant trial topline readout, the firm now sees a 50% probability of success for palazestrant in first-line HR+ mBC, up from a previously-predicted 30% chance, the analyst tells investors.
JPMorgan
NULL -> Overweight
maintain
$29 -> $32
2025-11-18
Reason
JPMorgan
Price Target
$29 -> $32
2025-11-18
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Olema Oncology to $32 from $29 and keeps an Overweight rating on the shares. The firm adjusted models in the smid-cap biotech space.
Oppenheimer
Oppenheimer
Outperform
upgrade
$22 -> $45
2025-11-18
Reason
Oppenheimer
Oppenheimer
Price Target
$22 -> $45
2025-11-18
upgrade
Outperform
Reason
Oppenheimer raised the firm's price target on Olema Oncology to $45 from $22 and keeps an Outperform rating on the shares. The firm notes Olema (OLMA) shares are reacting pre-market to the news that Roche's (RHHBY) lidERA trial hit on DFS in early-breast cancer. It's the first trial ever to show a clinical benefit head-to-head against an aromatase inhibitor. Oppenheimer says it was not expecting this readout as the entire narrative has been around Roche's evERA and persevERA trials. NULLtheless, the data are a welcome surprise, it adds. Early breast cancer is a multi-billion-dollar market, and one the firm did not have in its model. These data also incrementally derisk persevERA, which is testing oral SERDS against aromatase inhibitors in the frontline metastatic setting, Oppenheimer adds.
H.C. Wainwright
Buy
maintain
$28 -> $36
2025-11-18
Reason
H.C. Wainwright
Price Target
$28 -> $36
2025-11-18
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Olema Oncology to $36 from $28 and keeps a Buy rating on the shares. The firm views Roche's positive giredestrant results as "clearly indicative of the benefit" of oral selective estrogen receptor degraders. The adjuvant setting now could be another expansion indication for Olema's palazestrant, which creates "significant upside market opportunity as a setting where patients are on therapy for up to 10 years," the analyst tells investors in a research note.
Citi
Buy
maintain
$20 -> $21
2025-08-12
Reason
Citi
Price Target
$20 -> $21
2025-08-12
maintain
Buy
Reason
Citi raised the firm's price target on Olema Oncology to $21 from $20 and keeps a Buy rating on the shares. The firm also added a "90-day upside catalyst watch" on the shares ahead of the Phase 1b/2 mature data evaluating palazestrant plus ribo in ER+/HER2- advanced/metastatic breast cancer. Citi believes presenting the data at an important medical meeting will bring visibility and further share upside.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Olema Pharmaceuticals Inc (OLMA.O) is -12.31, compared to its 5-year average forward P/E of -6.62. For a more detailed relative valuation and DCF analysis to assess Olema Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.62
Current PE
-12.31
Overvalued PE
0.27
Undervalued PE
-13.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.46
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.82
Undervalued EV/EBITDA
-9.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
20.46
Current PS
0.00
Overvalued PS
145.17
Undervalued PS
-104.26
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OLMA News & Events

Events Timeline

(ET)
2025-11-19
07:12:18
Olema Oncology sets price for 10 million shares at $19.00 in public offering with underwriters
select
2025-11-18 (ET)
2025-11-18
16:54:31
Olema Oncology Reveals Offering of Common Stock and Warrants, Amount Not Disclosed
select
2025-11-10 (ET)
2025-11-10
07:14:15
Olema Oncology Announces Q3 Earnings Per Share of 49 Cents, Exceeding Consensus Estimate of 45 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03Globenewswire
Olema Grants 65,000 Stock Options to New Employees to Enhance Talent Acquisition
  • Stock Option Grant: Olema Pharmaceuticals granted 65,000 stock options to two new employees effective December 1, 2025, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in breast cancer treatment.
  • Incentive Plan: These options are awarded under the company's 2022 Inducement Plan, vesting over four years with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, ensuring continuous employee engagement with Olema.
  • Exercise Price: The options have an exercise price of $27.95 per share, equal to the last reported sale price on December 1, 2025, which aligns employee incentives closely with the company's performance.
  • Strategic Implications: By implementing this incentive measure, Olema not only attracts industry talent but also enhances its innovation capacity and market position in the rapidly evolving biopharmaceutical sector.
[object Object]
Preview
5.0
12-03Newsfilter
Olema Pharmaceuticals Grants 65,000 Stock Options to New Employees
  • Employee Incentive Program: Olema Pharmaceuticals granted 65,000 stock options to two new employees on December 1, 2025, aimed at attracting talent and enhancing employee loyalty, which will improve overall operational efficiency.
  • Option Details: The stock options have an exercise price of $27.95 per share, equal to the last reported sale price on the grant date, vesting over four years with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, ensuring long-term employee retention.
  • Compliance Disclosure: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating Olema's transparency and adherence to regulatory requirements, which helps to bolster investor confidence.
  • Company Strategic Direction: Olema focuses on developing targeted therapies for breast cancer, currently conducting two Phase 3 clinical trials, and the stock option grants not only incentivize new employees but also reflect the company's confidence in future R&D and market expansion.
[object Object]
Preview
6.0
11-22Benzinga
Goldman Sachs Reaffirms Buy Rating on Olema Pharmaceuticals, Increases Price Target to $26

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Olema Pharmaceuticals Inc (OLMA) stock price today?

The current price of OLMA is 27.64 USD — it has increased 1.43 % in the last trading day.

arrow icon

What is Olema Pharmaceuticals Inc (OLMA)'s business?

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

arrow icon

What is the price predicton of OLMA Stock?

Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 34.40 USD with a low forecast of 20.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Olema Pharmaceuticals Inc (OLMA)'s revenue for the last quarter?

Olema Pharmaceuticals Inc revenue for the last quarter amounts to -45.88M USD, increased 21.95 % YoY.

arrow icon

What is Olema Pharmaceuticals Inc (OLMA)'s earnings per share (EPS) for the last quarter?

Olema Pharmaceuticals Inc. EPS for the last quarter amounts to -34527000.00 USD, increased 27.80 % YoY.

arrow icon

What changes have occurred in the market's expectations for Olema Pharmaceuticals Inc (OLMA)'s fundamentals?

The market is revising Downward the revenue expectations for Olema Pharmaceuticals, Inc. (OLMA) for FY2026, with the revenue forecasts being adjusted by -12.5% over the past three months. During the same period, the stock price has changed by 232.61%.
arrow icon

How many employees does Olema Pharmaceuticals Inc (OLMA). have?

Olema Pharmaceuticals Inc (OLMA) has 96 emplpoyees as of December 05 2025.

arrow icon

What is Olema Pharmaceuticals Inc (OLMA) market cap?

Today OLMA has the market capitalization of 2.17B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free